Back to BAX Stock Lookup

Baxter Int'l (BAX) – Press Releases

Nov 19, 2014 08:00 AM Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
Nov 13, 2014 04:15 PM Baxter to Present at the 26th Annual Piper Jaffray Healthcare Conference
Nov 11, 2014 09:05 AM Baxter Declares Quarterly Dividend
Nov 6, 2014 08:30 AM Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
Nov 5, 2014 04:15 PM Baxter to Present at the Stifel 2014 Healthcare Conference
Oct 30, 2014 09:00 AM Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability Endpoints in Phase 2/3 Study
Oct 24, 2014 09:00 AM FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A
Oct 22, 2014 04:15 PM Baxter to Present at the 2014 Credit Suisse Healthcare Conference
Oct 20, 2014 09:00 AM Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency
Oct 16, 2014 07:00 AM Baxter’s Third Quarter Financial Results Exceed Guidance
Oct 9, 2014 04:35 PM Baxter International Third Quarter 2014 Financial Results Conference Call
Oct 8, 2014 09:15 AM Baxter Recognized for Commitment to Women's Healthcare Careers
Oct 3, 2014 07:00 AM Rockwell Medical Enters Into Exclusive Long-Term Agreement With Baxter Healthcare to Commercialize Rockwell's Hemodialysis Concentrates
Oct 1, 2014 09:15 AM Baxter International Inc. Recognized by Healthcare Businesswomen’s Association with ACE Award for Its Baxter Women Leaders Business Resource Group
Sep 29, 2014 04:15 PM Baxter to Form New Global Innovation and R&D Center near Boston for Its Biopharmaceuticals Business
Sep 26, 2014 04:56 AM PharmaEngine and Merrimack Amend MM-398 License Agreement
Sep 25, 2014 04:15 PM Baxter International Third Quarter 2014 Financial Results Conference Call
Sep 24, 2014 07:00 AM Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398
Sep 15, 2014 09:00 AM FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B
Sep 12, 2014 07:02 PM FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency
Sep 10, 2014 04:30 PM Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

Back to BAX Stock Lookup